Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

Heart teams playing a major role in coronary revascularization decisions
Sunil Rao, MD, discusses the heart team approach in the context of deciding what is best for the patient between bypass surgery and percutaneous coronary intervention.
FDA clears opportunistic AI for detecting cardiothoracic issues in CT scans
“Coronary calcium revealed long ago that atherosclerosis begins well before symptoms. AI-CVD extends that insight by enabling systematic identification of patients who are unaware of their cardiovascular risk using CT scans that already exist,” said Arthur Agatston, MD.
Office-based interventional labs see boost in pay in 2026
CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule.
ASNC reports shortage of cardiac amyloidosis radiotracers
The two vendors involved say supplies of PYP and HDP could be disrupted for months.
FDA clears MRI-compatible EP mapping catheter
This represents the first FDA clearance for Imricor Medical Systems. "It’s an exciting achievement and a date to be noted and remembered," CEO Steve Wedan said in a statement.

Sunil Rao, MD, director, interventional cardiology, cardiac catheterization laboratory, NYU Langone Heart, professor, Department of Medicine, the Leon H. Charney Division of Cardiology, NYU Grossman School of Medicine, discusses the heart team approach in the context to determining what is best for the patient in terms of bypass surgery or percutaneous coronary intervention.

Heart teams playing a major role in coronary revascularization decisions

Sunil Rao, MD, discusses the heart team approach in the context of deciding what is best for the patient between bypass surgery and percutaneous coronary intervention.

The U.S. Food and Drug Administration (FDA) has cleared HeartLung Corporation's AI-CVD, an artificial intelligence (AI) algorithm that looks at 11 different opportunistic health screening assessments on chest CT exams ordered for any reason.

FDA clears opportunistic AI for detecting cardiothoracic issues in CT scans

“Coronary calcium revealed long ago that atherosclerosis begins well before symptoms. AI-CVD extends that insight by enabling systematic identification of patients who are unaware of their cardiovascular risk using CT scans that already exist,” said Arthur Agatston, MD.

Hospital patient bays recovery Banner Health and Atlas Ambulatory Surgical Center (ASC) in Sun City, Arizona.

Office-based interventional labs see boost in pay in 2026

CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule.

ASNC reports shortage of cardiac amyloidosis radiotracers

The two vendors involved say supplies of PYP and HDP could be disrupted for months.

FDA clears MRI-compatible EP mapping catheter

This represents the first FDA clearance for Imricor Medical Systems. "It’s an exciting achievement and a date to be noted and remembered," CEO Steve Wedan said in a statement.

Boston Scientific Farapoint pulsed field ablation (PFA) catheter

FDA approves Boston Scientific’s Farapoint PFA catheter

The newest addition to the company's Farapulse PFA Platform was specifically approved to perform cavotricuspid isthmus ablation.

Mirvat Alasnag, MD, FACP, FACC, FSCAI, FSCCT, director of catheterization laboratory and research, King Fahd Armed Forces Hospital, Jeddah-Saudi Arabia, Ditrector of TCT Middle East, and member of Society of Cardiovascular CT (SCCT) Education Committee, explains how the society it translating its educational content into other languages to help a wider international audience of clinicians. SCCT is working to expand its international membership and this is a big part of that strategy.

SCCT expands CCTA education overseas

SCCT has made it a priority to help clinicians from all over the world learn more about CCTA as the modality continues to transform patient care.

PET-CT imaging of 124-I evuzamitide and SPECT-CT imaging of 99mTc-p5+14 showed radiotracer uptake in both AL and ATTR amyloid throughout the myocardium. Emily B. Martin, Anne Kassira, Alan Stuckey, et al. A tale of two tracers - Amyloid imaging with investigational radiotracers iodine (124I) evuzamitide and 99mTc-p5+14 (AT-05). https://www.journalofnuclearcardiology.org/article/S1071-3581(25)00325-3/abstract.

Bayer expands into molecular imaging with cardiac amyloidosis tracer acquisitions

Bayer is acquiring two cardiac amyloidosis radiotracers from Attralus, one for PET and one for SPECT. The SPECT tracer is also a theranostic agent to both image and treat amyloidosis.